Targeting pathologic macrophage activation through inhibition of MyD88 to attenuate laryngotracheal stenosis
通过抑制 MyD88 靶向病理性巨噬细胞激活以减轻喉气管狭窄
基本信息
- 批准号:10644555
- 负责人:
- 金额:$ 19.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:AdultAttenuatedAutomobile DrivingBiological Response ModifiersBiopsyBypassCD4 Positive T LymphocytesCellsCollagenCommunication impairmentCritical IllnessCritical PathwaysDataDevelopmentDiseaseDysphoniaDyspneaExcisionExperimental DesignsFibrosisFlow CytometryFoundationsGene ExpressionGoalsHistologicHumanIatrogenesisImmuneImmune TargetingImmune responseImmunologyImmunophenotypingInflammationInflammatory InfiltrateInjuryInterleukin-1 betaInterventionIntratracheal IntubationIntubationInvestigationKnowledgeLaboratoriesLamina PropriaLaryngeal DiseasesLarynxLeadLifeMacrophageMacrophage ActivationMediatingMedicalMentorsModelingMolecularMucous MembraneMusOperative Surgical ProceduresPathogenesisPathologicPathway interactionsPatientsPatternPhenotypePhysiologicalPopulationProteinsRegulatory PathwayResearchResearch TrainingResectedRoleS100A8 geneSecondary toSerumSignal PathwaySignal TransductionSourceStenosisSubglottis structureTLR4 geneTherapeutic InterventionTissuesToll-like receptorsTracheaTracheostomy procedureTransgenic Organismsbiomarker developmentcandidate markercareercytokineexperiencegenetic regulatory proteinimprovedmouse modelpathogenpreventprotein expressionreceptorsingle-cell RNA sequencingskillstargeted treatmenttreatment strategywound healing
项目摘要
Project Summary:
Laryngotracheal Stenosis (LTS) is the pathologic narrowing of the larynx, subglottis, and trachea
secondary to mucosal injury from prolonged intubation. This narrowing leads to dyspnea, dysphonia, and can
rapidly progress to airway compromise. Therapeutic interventions for the management of LTS are limited to
serial dilation, tracheal resection, or permanent tracheostomy which further impairs communication. Medical
therapies for LTS are limited by our poor understanding of LTS pathogenesis. Improved understanding of the
mechanisms promoting LTS is needed to improve treatment of this debilitating disease.
Previous investigation has revealed that an intact immune response is critical to the development of LTS.
Characterization of the immune response in LTS has demonstrated increased populations of CD4+ T-cells and
macrophages. Preliminary studies in a murine LTS model reveal that depletion of the macrophage population
attenuates LTS fibrosis, implicating their pathologic role. However, the local immune mediators and cell signaling
pathways promoting pathologic macrophages in LTS are unknown.
Macrophage activation is regulated through stimulation of Toll-like receptors (TLRs). TLRs are highly
conserved receptors recognizing Pathogen or Damage Associated Molecular Patterns (PAMPs/DAMPs) and
lead to downstream activation of regulatory proteins controlling phenotype. Using single cell RNA sequencing
the PI has demonstrates increased expression of the TLR4-MyD88 signaling pathway in LTS macrophages.
Furthermore, we have identified increased expression of the DAMP S100A8/A9 in LTS tissue. S100A8/A9 is a
known activator of TLR4-MyD88 signaling, and worsens fibrosis in our murine LTS model. These findings
indicate that TLR4-MyD88 signaling pathways in macrophages may be critical to LTS pathogenesis. However,
the relationship between S100A8/A9, TLR4-MyD88 signaling, and pathologic macrophages has not been
explored in LTS or other fibrotic diseases, and may represent a critical signaling axis driving pathologic fibrosis.
For this study, we will elucidate the signaling networks promoting pathologic macrophages in laryngotracheal
stenosis. In Aim 1 we will assess effect of S100A8/A9 on macrophage phenotype and function in a murine LTS
model, establish that S100A8/A9s profibrotic effect is mediated by macrophages, and identify the key sources
of pathologic S100A8/A9 in human LTS and a murine model. In Aim 2, we will demonstrate the critical role of
TLR4-MyD88 signaling in promoting pathologic macrophages in LTS, and elucidate the role of IL1β in promoting
LTS fibrosis. Finally, in Aim 3 we will assess S100A8/A9 as a candidate biomarker for the development of
laryngotracheal stenosis in patients who have had prolonged intubation. Collectively, this application will lead to
an in-depth understanding of the cell signaling networks promoting dysregulated macrophage mediated
inflammation and subsequent fibrosis in LTS. The identification of key regulatory pathways promoting pathologic
macrophages in LTS will serve as the foundation for targeted treatment strategies that attenuate fibrosis.
项目总结:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevin Motz其他文献
Kevin Motz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 19.76万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 19.76万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 19.76万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 19.76万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 19.76万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 19.76万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 19.76万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 19.76万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 19.76万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 19.76万 - 项目类别:
Idea to Innovation